CAS: 102130-43-8; Potassium (2R,4Ar,6Ar,7S,9R,11As,11Br)-7-Hydroxy-2-(((2R,3R,4R,5R,6R)-6-(Hydroxymethyl)-3-((3-Methylbutanoyl)Oxy)-5-(Sulfonatooxy)-4-(Sulfooxy)Tetrahydro-2H-Pyran-2-yl)Oxy)-11B-Methyl-8-Methylenetetradecahydro-6A,9-Methanocyclohepta[a]Naphthalene-4-Carbox
该化合物是一个复杂的有机化合物,其特点是独特的结构特征,包括类固醇的脊柱和多种功能组;该化合物含有一种有助于其酸性,有助于其溶解于极地溶剂的碳盒酸性酸味,以及一个增加其溶液溶液的氢氧基组;全氟辛烷磺酸组的存在表明其具有很强的离子特性,因此有可能成为药物或生物化学应用的候选物;钾盐表显示水环境中的稳定性和溶性得到加强,有利于生物活动;它包含一个甘蓝基体的复杂的玻璃合金模式,可能会影响其与生物系统的互动,有可能影响其药用植物和生物活性;总体而言,该化合物体现了天然产品衍生物的复杂性及其在包括药用化学和药物开发在内的各种科学领域的潜在用途.
- 英文名称Potassium (2R,4Ar,6Ar,7S,9R,11As,11Br)-7-Hydroxy-2-(((2R,3R,4R,5R,6R)-6-(Hydroxymethyl)-3-((3-Methylbutanoyl)Oxy)-5-(Sulfonatooxy)-4-(Sulfooxy)Tetrahydro-2H-Pyran-2-yl)Oxy)-11B-Methyl-8-Methylenetetradecahydro-6A,9-Methanocyclohepta[a]Naphthalene-4-Carbox
- 中文名称苍术苷二钾盐
- IUPAC名称potassium (2R,4aR,6aR,7S,9R,11aS,11bR)-7-hydroxy-2-(((2R,3R,4R,5R,6R)-6-(hydroxymethyl)-3-((3-methylbutanoyl)oxy)-5-(sulfonatooxy)-4-(sulfooxy)tetrahydro-2H-pyran-2-yl)oxy)-11b-methyl-8-methylenetetradecahydro-6a,9-methanocyclohepta[a]naphthalene-4-carboxylate
- 其它别名[(2S,3R,4R,5R,6R)-2-[[(1R,4R,5R,7R,9R,10S,13R,15S)-5-Carboxy-15-Hydroxy-9-Methyl-14-Methylidene-7-Tetracyclo[11.2.1.01,10.04,9]Hexadecanyl]Oxy]-6-(Hydroxymethyl)-3-(3-Meth
- CAS编号102130-43-8
- MFCD编号:MFCD00078810
- EINECS号:634-446-8
- 分子式:C30H44K2O16S2分子量:803.0
- 产品CID: 47914
- 同类组份化合物CAS17754-44-8 (free acid)102130-43-8 (potassium)
- 产品分类Chemistry → Asymmetric Synthesis → Chiral Building Blocks | Sulfonates | Ethers | Tetrahydropyrans | Esters | Carboxylic Acid Salts | Inhibitors/Agonists → Metabolic Enzyme → Mitochondrial Metabolism | Inhibitors/Agonists → PI3K/Akt/mTOR → AMPK | Aliphatic Cyclic Hydrocarbons | Inhibitors/Agonists → PI3K/Akt/mTOR → mTOR | Alcohols | Sulfonic Acids | Aliphatic Heterocycles | Alkenyls
物理性质
MSDS等安全信息
欧盟法规
C&L通报合成工艺路线路线简述
供应商参考报价(招募中)
品牌试剂参考报价(招募中)
📌 第三方产品分析报告
主要参考文献
1: Stewart MJ, Steenkamp V. The biochemistry and toxicity of atractyloside: a review. Ther Drug Monit. 2000 Dec;22(6):641-9. doi: 10.1097/00007691-200012000-00001. 36(4):335-46. doi: 10.1016/s0278-6915(98)00002-7. 9(6):489-97. doi: 10.1016/s0022-2828(77)80028-x. 43(3):590-597. doi: 10.1002/jssc.201900888. Epub 2019 Dec 2. 22(8):2973-5. doi: 10.1016/j.bmcl.2012.02.040. Epub 2012 Feb 22. 24(13):7417-7426. doi: 10.1111/jcmm.15357. Epub 2020 May 29.
7: Wu DL, Wang TS, Liu HJ, Zhang W, Tong XH, Peng DY, Kong LY. Study on the mechanism of Wuzi-Yanzong-Wan-medicated serum interfering with the mitochondrial permeability transition pore in the GC-2 cell induced by atractyloside. Chin J Nat Med. 2022 Apr;20(4):282-289. doi: 10.1016/S1875-5364(22)60153-5. 18(1):39-46. doi: 10.1016/j.str.2009.11.009. 131(2):213-8. doi: 10.1016/0014-5793(81)80370-5.
92:178-80. doi: 10.1016/0926-6569(64)90290-1. 75(6):1070-5. doi: 10.1021/np300080w. Epub 2012 May 17. 56(2):194-7. doi: 10.1016/0014-5793(75)81089-1. 18(2):2018-28. doi: 10.3390/molecules18022018.
合成参考文献
参考文献:10.1016/j.antiviral.2011.06.006
摘要:Campagnola G, Gong P, Peersen OB. High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors. Antiviral Research. 2011 Sep;91(3):241–51. doi: 10.1016/j.antiviral.2011.06.006.
📝 需求与反馈
尽可能描述清楚需求与问题信息
